COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

ABSTRACTCONTEXT AND OBJECTIVEWe propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.

Download Full-text

From nowhere to nowhere. Homelessness and incarceration: a systematic review and meta-analysis

International Journal of Prisoner Health ◽

10.1108/ijph-01-2021-0010 ◽

2021 ◽

Vol ahead-of-print (ahead-of-print) ◽

Author(s):

Ahmad Y. Bashir ◽

Noreen Moloney ◽

Musaab E. Elzain ◽

Isabelle Delaunois ◽

Ali Sheikhi ◽

...

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Grey Literature ◽

Mental Illnesses ◽

Significant Heterogeneity ◽

Inclusion Criteria ◽

Systematic Review Methodology ◽

Content Type ◽

Targeted Interventions ◽

The Usa

Purpose This study aims to review international literature systematically to estimate the prevalence of homelessness among incarcerated persons at the time of imprisonment and the time of discharge. Design/methodology/approach A systematic review methodology was used to identify quantitative observational studies that looked at the prevalence of homelessness at the time of imprisonment, or up to 30 days prior to that point (initial homelessness), and at the time of discharge from prisons. Studies reported in English from inception to 11 September 2019 were searched for using eight databases (PsycInfo, Medline, Embase, CINAHL, PsycArticles, Scopus, Web of Science and the Campbell Collaboration), in addition to grey literature. Studies were screened independently by three researchers. Results of studies meeting inclusion criteria were meta-analysed using a random effects model to generate pooled prevalence data. Findings A total of 18 out of 2,131 studies met the inclusion criteria. All studies originated from the USA, Canada, UK, Ireland or Australia. The estimated prevalence of initial homelessness was 23.41% and at time of discharge was 29.94%. Substantial heterogeneity was observed among studies. Originality/value People in prisons are over twenty times more likely to be homeless than those in the general population. This is likely attributable to a range of health and social factors. Studies in this analysis suggest higher rates of homelessness in minority populations and among those with mental illnesses and neurodevelopmental disorders. While there was significant heterogeneity among studies, the results highlight the global burden of this issue and a clear necessity for targeted interventions to address homelessness in this population.

Download Full-text

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

Rheumatology ◽

10.1093/rheumatology/keu172 ◽

2014 ◽

Vol 53 (10) ◽

pp. 1872-1885 ◽

Cited By ~ 82

Author(s):

Alejandro Souto ◽

José Ramón Maneiro ◽

Eva Salgado ◽

Loreto Carmona ◽

Juan J. Gomez-Reino

Keyword(s):

Systematic Review ◽

Randomized Controlled Trials ◽

Inflammatory Diseases ◽

Meta Analysis ◽

Controlled Trials ◽

Randomized Controlled ◽

Immune Mediated

Download Full-text

COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

10.1590/scielopreprints.349 ◽

2020 ◽

Author(s):

Maria Eduarda dos Santos Puga ◽

Aline Pereira da Rocha ◽

Alvaro Nagib Atallah ◽

Ana Carolina Pereira Nunes Pinto ◽

César Ramos Rocha-Filho ◽

...

Keyword(s):

Systematic Review ◽

Inflammatory Diseases ◽

Pharmacological Treatments ◽

Immune Mediated

Download Full-text

Faculty Opinions recommendation of The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969501.793470033 ◽

2013 ◽

Author(s):

Kamran Ghoreschi ◽

Amir S Yazdi

Keyword(s):

Systematic Review ◽

Inflammatory Diseases ◽

Meta Analysis ◽

Review Of The Literature ◽

Immune Mediated

Download Full-text

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

Autoimmunity Reviews ◽

10.1016/j.autrev.2021.102927 ◽

2021 ◽

pp. 102927

Author(s):

Anuraag Jena ◽

Shubhra Mishra ◽

Parakkal Deepak ◽

Praveen Kumar-M ◽

Aman Sharma ◽

...

Keyword(s):

Systematic Review ◽

Inflammatory Diseases ◽

Meta Analysis ◽

Immune Mediated

Download Full-text

Pre-Morbid Obesity is Associated with Increased Risk of Developing Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis

Gastroenterology ◽

10.1016/s0016-5085(17)33310-3 ◽

2017 ◽

Vol 152 (5) ◽

pp. S976-S977 ◽

Cited By ~ 5

Author(s):

Siddharth Singh ◽

Mathurin Fumery ◽

Katherine Shaffer ◽

Abha G. Singh ◽

Larry Prokop ◽

...

Keyword(s):

Systematic Review ◽

Morbid Obesity ◽

Inflammatory Diseases ◽

Meta Analysis ◽

Immune Mediated ◽

Increased Risk

Download Full-text

Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn’s disease

Therapeutic Advances in Gastroenterology ◽

10.1177/17562848211004839 ◽

2021 ◽

Vol 14 ◽

pp. 175628482110048

Author(s):

Mohamed Attauabi ◽

Mirabella Zhao ◽

Flemming Bendtsen ◽

Johan Burisch

Keyword(s):

Systematic Review ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Inflammatory Diseases ◽

Meta Analysis ◽

Random Effect ◽

Immune Mediated ◽

Increased Risk ◽

The Impact ◽

Upper Gastrointestinal

Background: Patients with Crohn’s disease (CD) are at increased risk of co-occurring immune-mediated inflammatory diseases (IMIDs). As discrepancy exists regarding the phenotypic presentation of CD among patients with such co-occurring IMIDs, we aimed to conduct a systematic review with meta-analysis characterizing the phenotype of CD among this subgroup of patients. Methods: PubMed, Embase, and Scopus were searched from their earliest records to October 2019 for studies reporting the behavior and localization of CD according to the Vienna or Montreal Classifications and CD-related surgery in patients with co-occurring IMIDs. These studies were the subject of a random effect meta-analysis. Results: After reviewing 24,413 studies, we identified a total of 23 studies comprising 1572 and 35,043 CD patients with and without co-occurring IMIDs, respectively, that fulfilled our inclusion criteria. Overall, patients with co-occurring IMIDs were more likely to have upper gastrointestinal inflammation than were patients without co-occurring IMIDs [relative risk (RR) = 1.49 (95% confidence interval (CI) 1.09–2.04), p = 0.01, I2 = 7%]. In addition, presence of primary sclerosing cholangitis (PSC) was associated with a lower occurrence of ileal affection [RR = 0.44 (95% CI 0.24–0.81), p < 0.01, I2 = 32%], increased occurrence of colonic affection [RR = 1.78 (95% CI 1.33–2.38), p < 0.01, I2 = 32%] and an increased likelihood of non-stricturing and non-penetrating behavior [RR = 1.43 (95% CI 0.97–2.11), p = 0.07, I2 = 86%]. The latter reached significance when cumulating different IMIDs [RR = 1.30 (95% CI 1.09–1.55), p < 0.01, I2 = 88%]. CD patients with PSC also underwent fewer CD-related surgeries [RR = 0.55 (95% CI 0.34–0.88), p = 0.01, I2 = 0%], irrespective of CD location or behavior. Conclusion: This study emphasizes that CD patients with co-existing PSC are likely to have a unique inflammatory distribution primarily confined to the colon, while patients with IMIDs in general have higher likelihood of affection of upper gastrointestinal tract and a non-stricturing and non-penetrating behavior. As such a phenotype of CD is typically associated with a milder disease course; future studies are needed to confirm these results.

Download Full-text